Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...

An experimental drug can delay disability progression in advanced multiple sclerosis patients Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is an ...

Physical activity was associated with a lower risk of disability progression in multiple sclerosis (MS), longitudinal data showed. Compared with low physical activity, the risk of confirmed disability ...

COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The Phase 3 HERCULES ...

Background Physical activity has been associated with neuroprotective and immunomodulatory benefits, potentially influencing ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

High fish consumption was linked with slower disability progression in MS. Benefits were seen for both lean and oily fish consumption. Protective effects were strongest with consistent fish ...

Multiple sclerosis (MS) is a disease that affects the brain and spinal cord. It can cause fatigue, trouble with balance and coordination, muscle weakness, and vision problems. Having MS doesn’t ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...